Biotechnology major Biocon Thursday reported a 64 per cent jump in consolidated net profit to Rs 213.7 crore for the fourth quarter ended March 2019, mainly on account of robust growth in biologics and research services segments.
The company had posted a net profit of Rs 130.4 crore for the corresponding period of the previous fiscal, Biocon said in a filing to BSE.
Consolidated total income of the company rose to Rs 1,557 crore for the March quarter. It was Rs 1,237 crore for the same period a year ago.
Biocon Chairperson and MD Kiran Mazumdar-Shaw said: "Our Q4 FY19 performance was led by robust growth in our biologics and research services business segments, supported by a significant growth in the small molecules business."
Disclaimer: No Business Standard Journalist was involved in creation of this content